Editorial
doi: 10.1200/JCO.2010.29.3407.
Epub 2010 Oct 4.
EGFR antibodies in colorectal cancer: where do they belong?
- PMID: 20921457
- DOI: 10.1200/JCO.2010.29.3407
Item in Clipboard
Editorial
EGFR antibodies in colorectal cancer: where do they belong?
J Clin Oncol.
.
No abstract available
Comment on
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921462 Clinical Trial.
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921465 Clinical Trial.
Similar articles
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921462 Clinical Trial.
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921465 Clinical Trial.
-
Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96. Ann Surg. 2010. PMID: 20010090
-
Cetuximab in metastatic colorectal cancer.Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25. Expert Rev Anticancer Ther. 2012. PMID: 22594891 Review.
-
A novel K-ras mutation in colorectal cancer. A case report and literature review.Anticancer Res. 2009 Aug;29(8):3369-74. Anticancer Res. 2009. PMID: 19661358 Review.
Cited by
-
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.Int J Cancer. 2014 Jun 1;134(11):2513-22. doi: 10.1002/ijc.28384. Epub 2013 Aug 27. Int J Cancer. 2014. PMID: 23852704 Free PMC article. Review.
-
Endothelial cells in colorectal cancer.World J Gastrointest Oncol. 2019 Nov 15;11(11):946-956. doi: 10.4251/wjgo.v11.i11.946. World J Gastrointest Oncol. 2019. PMID: 31798776 Free PMC article. Review.
-
Recent advances of bispecific antibodies in solid tumors.J Hematol Oncol. 2017 Sep 20;10(1):155. doi: 10.1186/s13045-017-0522-z. J Hematol Oncol. 2017. PMID: 28931402 Free PMC article. Review.
-
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.J Mol Diagn. 2017 Mar;19(2):187-225. doi: 10.1016/j.jmoldx.2016.11.001. Epub 2017 Feb 6. J Mol Diagn. 2017. PMID: 28185757 Free PMC article.
-
Molecular Biomarkers for the Evaluation of Colorectal Cancer.Am J Clin Pathol. 2017 Mar;147(3):221-260. doi: 10.1093/ajcp/aqw209. Epub 2017 Feb 3. Am J Clin Pathol. 2017. PMID: 28165529 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
